The monoclonal antibodies in veterinary health market size is estimated to be USD 697.8 million in 2022 and is expected to witness a CAGR of 16.91% during the forecast period 2023-2033. Growing research and development investment by industry participants for the creation of cancer treatments and surge in prevalence of cancer specifically in canines are some of the factors contributing to the market growth. Furthermore, rise in the adoption of pets, escalating incidence of canine atopic dermatitis are other factors supporting the market growth. However, high cost of vaccines is expected to hinder the growth.

Rise in the adoption of pets is predicted to propel the market growth during the forecast period. Around 90.5 million families, or 70% of American households, owned a pet as of 2021–2022, according to the American Pet Products Association’s (APPA) National Pet Owners Survey. According to the same report, there were 3.9 million insured pets nationwide in 2021, a 28% rise from 2020.

Escalating incidence of canine atopic dermatitis is expected to fuel the market growth during the projected period. A hereditary clinical syndrome in domestic dogs is canine atopic dermatitis. Atopic dermatitis is also the most usual cause of itchy allergic skin condition in dogs. According to details released by Frontiers Media S.A. in October 2020, the disease is predicted to impact 10% to 15% of dogs overall. The article also noted that this number is probably going to rise over time.

Segmentation

 By Animal Type

The market is categorized into dogs and others. In 2022, the dogs segment accounted for the highest revenue share due to the market’s availability of canine monoclonal antibody products. Additionally, the number of dogs kept as pets is growing, which is driving up costs for their care and accelerating market expansion. The Pet Food Manufacturers’ Association reported that there were 12 million pet dogs in the United Kingdom as of 2021. 33% of households fell under this category. The others segment is anticipated to grow at the fastest rate over the projection period. Horses, cats, and livestock animals are examples of other animals. Along with the increasing use of pet insurance, rising prevalence of numerous chronic diseases in animals is also projected to boost market expansion. In addition, the American Society for the Prevention of Cruelty to Animals reports that compared to dogs, cats make up about 85.8 million of the country’s pet owners (78 million). This represents 35% of homes in terms of ownership.

 By Application

The market is categorized into pain, dermatology, others. In the global market, the dermatology segment accounted for the largest revenue share in 2022 owing to wide range of products available in this category. In addition, the rising prevalence of infectious skin disorders and atopic dermatitis in animals is anticipated to fuel market expansion. In Poland, S. pseudintermedius was present in both healthy and ill cats at rates of 2.49% and 7.61%, respectively, according to research by Scientific Reports in 2021. S. pseudintermedius, also termed as Staphylococcus pseudintermedius, is a bacterial infection that affects both cats and dogs. The Others segment is expected to grow at the fastest pace over the forecasted period. Cancer, arthritis, and different infectious diseases are among the other diseases. The development of novel therapeutic alternatives is the area of R&D that has shown the fastest growth.

By End User

The market is segmented into veterinary hospitals, others. In 2022, the veterinary hospitals segment accounted for the largest revenue share owing to the availability of new therapies. Additionally, the number of veterinary hospitals and doctors is increasing, which promotes the expansion of the market. There were 84,200 veterinarians in the United States in 2018, according to a Petpedia.co research. By 2029, it was predicted that this number will rise by about 14,200. The others segment is expected to expand at the highest CAGR during the forecast period. Clinics, research organizations, and academic institutions are among the entities included in the others segment. It is also projected that rising research efforts to create new monoclonal antibody therapy choices will propel market expansion. Additionally, high consumer knowledge of cutting-edge veterinary therapeutic options is anticipated to fuel market expansion.

Regional Markets

In 2022, North America region accounted for the highest revenue in the monoclonal antibodies in veterinary health market and is expected to maintain its dominance during the forecast period. This is attributed to the several government and corporate sector initiatives, and rising popularity of pet insurance. Additionally, the presence of major companies in the U.S. is expected to spur market expansion. According to the North American Pet Health Insurance Association, Inc., the pet insurance market has been expanding at an impressive pace of 23.4% during the past several years. Additionally, 3.45 million pets were covered across North America as of the end of 2020. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecasted period due to the increasing presence of local players and the rising number of veterinary hospitals and clinics. The market is also anticipated to rise as a result of the rising adoption of pets, greater knowledge of their diseases, and the availability of alternate forms of therapy.

Competitor Insights

Some of the key players operating in the monoclonal antibodies in veterinary health market are Virbac, Invetx, Elanco, Boehringer Ingelheim GmbH, Nextmune, Bayer Animal Health, Kindred Biosciences, Inc., adivo GmbH, Merck & Co. Inc, Indian Immunologicals Ltd., and Zoetis.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Solensia, a medication for the pain treatment of feline osteoarthritis, was approved by the U.S. FDA in January 2022, according to a statement from Zoetis. Similar to this, in January 2022, Boehringer Ingelheim International GmbH announced that it has partnered with MabGenesis, a privately held biopharmaceutical company in Japan.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including animal type, application and end user from 2023 to 2033.

Report Scope:

Segmentation: Monoclonal Antibodies in Veterinary Health Market Report 2022 – 2033

Animal Type (Revenue, USD Million), 2022 – 2033

• Dogs
• Others

Application (Revenue, USD Million), 2022 – 2033

• Pain
• Dermatology
• Others

End user (Revenue, USD Million), 2022 – 2033

• Veterinary Hospitals
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA